Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 10 Issue 8, August 2011

In This Issue

Top of page ⤴

Comment

Top of page ⤴

News and Analysis

  • Pharmaceutical–academia deals have been stealing headlines this year, but more complex models of pharma–pharma collaboration are increasingly being seen as potential solutions to industry's most intractable challenges.

    • Asher Mullard
    News and Analysis
  • The PI3K–AKT–mTOR pathway has long been an attractive oncology target. But with top-line results from the most advanced AKT inhibitor due soon, many questions remain over which targets to hit and how to combine agents.

    • David Holmes
    News and Analysis
Top of page ⤴

News in Brief

Top of page ⤴

Biobusiness Briefs

Top of page ⤴

News and Analysis

Top of page ⤴

Patent Watch

Top of page ⤴

An Audience With

  • Robert Dworkin, Director of ACTION, discusses the public–private partnership's plans to revamp clinical trial design for pain drugs.

    An Audience With
Top of page ⤴

From the Analyst's Couch

Top of page ⤴

Fresh from the Pipeline

    • Christopher J. Logothetis
    • Eleni Efstathiou
    • Peter Kirkpatrick
    Fresh from the Pipeline
Top of page ⤴

Research Highlight

Top of page ⤴

Analysis

  • Schiöth and colleagues examine the drugs approved by the US Food and Drug Administration over the past 30 years and analyse the interactions of these drugs with therapeutic targets encoded by the human genome, identifying 435 effect-mediating drug targets. They also analyse trends in the introduction of drugs that modulate previously unexploited targets, and discuss the network pharmacology of the drugs in the data set.

    • Mathias Rask-Andersen
    • Markus Sällman Almén
    • Helgi B. Schiöth
    Analysis
Top of page ⤴

Review Article

  • Although our insight into antitumour immune responses has increased substantially in the past few decades, the development of immunotherapy for cancer has been hampered by challenges including the identification of optimal treatment strategies and methods to evaluate them. However, as Punt and colleagues discuss, the recent positive results of clinical trials with novel immunological drugs, as well as the unexpected finding of a positive interaction between immunotherapy and chemotherapy, may herald a new era for cancer immunotherapy.

    • W. Joost Lesterhuis
    • John B. A. G. Haanen
    • Cornelis J. A. Punt
    Review Article
  • Transient receptor potential (TRP) channels are a diverse family of cation channels. Here, the authors discuss recent developments in this area, highlight recent developments and setbacks in the field of pain research and analyse TRP channels as targets for skin, pulmonary and urological disorders.

    • Magdalene M. Moran
    • Michael Allen McAlexander
    • Arpad Szallasi
    Review Article
  • The development of effective therapies for neuromuscular disorders is hampered by considerable challenges, including the abundance of skeletal muscle within the body and the multisystemic nature of many of these diseases. Here, Muntoni and Wood review recent advances in the development of novel therapies that target RNA, which are exemplified by three disorders: Duchenne muscular dystrophy, myotonic dystrophy and spinal muscular atrophy.

    • Francesco Muntoni
    • Matthew J. A. Wood
    Review Article
Top of page ⤴

Search

Quick links